206 related articles for article (PubMed ID: 23855304)
1. Family with sequence similarity 3 gene family and nonalcoholic fatty liver disease.
Yang J; Guan Y
J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():105-11. PubMed ID: 23855304
[TBL] [Abstract][Full Text] [Related]
2. FAM3 gene family: A promising therapeutical target for NAFLD and type 2 diabetes.
Zhang X; Yang W; Wang J; Meng Y; Guan Y; Yang J
Metabolism; 2018 Apr; 81():71-82. PubMed ID: 29221790
[TBL] [Abstract][Full Text] [Related]
3. Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation.
Tilg H; Moschen A
Curr Opin Clin Nutr Metab Care; 2010 Jul; 13(4):391-6. PubMed ID: 20473151
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Activation of the FAM3C-HSF1-CaM Pathway Attenuates Hyperglycemia of Obese Diabetic Mice.
Chen Z; Ding L; Yang W; Wang J; Chen L; Chang Y; Geng B; Cui Q; Guan Y; Yang J
Diabetes; 2017 May; 66(5):1185-1197. PubMed ID: 28246289
[TBL] [Abstract][Full Text] [Related]
5. The potential role of genes in nonalcoholic fatty liver disease.
Day CP
Clin Liver Dis; 2004 Aug; 8(3):673-91, xi. PubMed ID: 15331069
[TBL] [Abstract][Full Text] [Related]
6. Activin A in nonalcoholic fatty liver disease.
Yndestad A; Haukeland JW; Dahl TB; Halvorsen B; Aukrust P
Vitam Horm; 2011; 85():323-42. PubMed ID: 21353887
[TBL] [Abstract][Full Text] [Related]
7. From the metabolic syndrome to NAFLD or vice versa?
Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H
Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824
[TBL] [Abstract][Full Text] [Related]
9. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model.
Shindo N; Fujisawa T; Sugimoto K; Nojima K; Oze-Fukai A; Yoshikawa Y; Wang X; Yasuda O; Ikegami H; Rakugi H
J Hepatol; 2010 Jun; 52(6):903-12. PubMed ID: 20392512
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
[TBL] [Abstract][Full Text] [Related]
11. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease.
Byrne CD; Targher G
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1155-61. PubMed ID: 24743428
[TBL] [Abstract][Full Text] [Related]
12. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
Larter CZ; Chitturi S; Heydet D; Farrell GC
J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
[TBL] [Abstract][Full Text] [Related]
13. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
Scorletti E; Byrne CD
Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
Pettinelli P; Obregón AM; Videla LA
Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
[TBL] [Abstract][Full Text] [Related]
15. FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis.
Wang C; Chi Y; Li J; Miao Y; Li S; Su W; Jia S; Chen Z; Du S; Zhang X; Zhou Y; Wu W; Zhu M; Wang Z; Yang H; Xu G; Wang S; Yang J; Guan Y
Hepatology; 2014 May; 59(5):1779-90. PubMed ID: 24806753
[TBL] [Abstract][Full Text] [Related]
16. [The relationship between insulin resistance and adiponectin gene expression in nonalcoholic fatty liver disease].
Yang H; Li YY; Nie YQ; Zhou YJ; DU YL; Sha WH; Hong Y
Zhonghua Gan Zang Bing Za Zhi; 2007 Jul; 15(7):525-8. PubMed ID: 17669243
[TBL] [Abstract][Full Text] [Related]
17. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance.
Asrih M; Jornayvaz FR
J Endocrinol; 2013 Sep; 218(3):R25-36. PubMed ID: 23833274
[TBL] [Abstract][Full Text] [Related]
18. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
Wang Q; Jiang L; Wang J; Li S; Yu Y; You J; Zeng R; Gao X; Rui L; Li W; Liu Y
Hepatology; 2009 Apr; 49(4):1166-75. PubMed ID: 19177596
[TBL] [Abstract][Full Text] [Related]
19. Fatty liver: role of inflammation and fatty acid nutrition.
Byrne CD
Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):265-71. PubMed ID: 20189787
[TBL] [Abstract][Full Text] [Related]
20. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
Takahashi N; Qi Y; Patel HR; Ahima RS
J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
